M22-574: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy
Condition: Multiple Myeloma
Sponsor: AbbVie
Full Title
Protocol M22-574: A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Study Treatment
BCMAxCD3 bispecific antibody ABBV-383 vs standard approved therapy
Eligibility/Info
Relapsed/refractory multiple myeloma treated with at least 2 prior lines of therapy. Prior therapy must have included an immunomodulating agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
